Cingulate Sets Sights On $18bn ADHD Market With Precision Timed-Release Approach
Executive Summary
Emerging Company Profile: The US firm’s lead candidate contains a gold standard ADHD simulant packaged in a compressed tablet that releases the ingredient at timed intervals to address symptoms for up to 16 hours.
You may also be interested in...
Apellis Bounces Back After Needle Discontinuation Amid Syfovre Safety Concerns
Real-world cases of retinal vasculitis linked with Syfovre for geographic atrophy in age-related macular degeneration may have resulted from a material used in a specific filter needle, the US firm revealed, as analysts remained optimistic on the product.
Geron’s Imetelstat Headed To US FDA Advisory Committee For MDS
Geron’s telomerase inhibitor will also get standard review for transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS), suggesting FDA reviewers may be less bullish on imetelstat’s clinical data than analysts have been.